[VIRTUAL] Melflufen efficacy in multiple myeloma with TP53 aberrations

[VIRTUAL] Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials

[VIRTUAL] U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression

[VIRTUAL] Analysis of tumor microenvironmental features to refine prognosis in patients with stage III colon cancer (NCCTG N0147, Alliance)

[VIRTUAL] Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial

[VIRTUAL] Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma

[VIRTUAL] HER2 expression and M2-like tumor infiltrating macrophages associated with Cabazitaxel activity in gastric cancer

[VIRTUAL] Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients

[VIRTUAL] Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)

[VIRTUAL] Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant

[VIRTUAL] Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

[VIRTUAL] A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort

[VIRTUAL] RASSF1 promoter hypermethylation is associated with activated CTNNB1 pathways in hepatocellular carcinoma

[VIRTUAL] Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

[VIRTUAL] Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study